Biosimilar prescription drugs prioritized for coverage in NWT

Public Service Announcement

The NWT Department of Health and Social Services has announced a six-month transition period for eligible Extended Health Benefit and Métis Health Benefit program clients to switch prescriptions to biosimilar drugs from their original biologic drug. A biosimilar drug is one that is designed to have active properties similar to those of a drug that has previously been licensed. Biosimilar drugs have previously been referred to as “generic” drugs.

After the six-month transition period, coverage under the respective programs will be prioritized for biosimilar drugs only.

Biosimilar drugs are very similar to, and just as safe and effective as their original biologic counterparts.

This biosimilar policy is consistent with the policies implemented in B.C., New Brunswick, Alberta, and Québec and will ensure fiscal responsibility while supporting the health and safety of residents who depend upon biologic prescriptions for their health.

Residents can make an appointment with their doctor to discuss the switch and any questions or concerns.

For more information see:


For media requests, please contact:

Umesh Sutendra

Department of Health and Social Services
Government of the Northwest Territories